The UK will implement its major clinical trials regulatory overhaul on 28 April 2026, introducing faster approvals and a more flexible, risk-based system, although some areas of regulatory and ethical alignment still require careful consideration.

MHRA CTR news item image

On 28 April 2026 , the most significant update to UK clinical trials regulations will come into force after a 12-month implementation period. The updates bring the UK Medicines for Human Use (Clinical Trials) Regulations into closer alignment with the current EU Clinical Trials Regulation.

Key changes include, but are not limited to:

  • The legal adoption of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals in Human Use (ICH) E6 GCP (R3) principles
  • A fast track notification route to allow lower-risk trials to start sooner
  • A 14-day assessment route for Phase I (healthy volunteers) studies
  • A combined review from the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authory (HRA) to streamline processes
  • The replacement of ‘Participant’ with ‘Subject’
  • An increased scope for the Chief Investigator
  • New MHRA capability to assess computer model simulations and in-silico trials

There are still potential conflicts between the Declaration of Helsinki and the amendment clinical trial regulations, particularly regarding the use of placebo or no intervention, urgent safety measures and post-trial provisions. It is stated that:

‘In practice, the principles of the Declaration and the amended Clinical Trials Regulations are aligned in regard to expectations.

Sponsors should aim to comply with both but where strict adherence to the Declaration would undermine UK statutory safeguards or operational feasibility, the MHRA expects sponsors to prioritise compliance with UK law while documenting the rationale for deviations’.

These reforms aim to demonstrate that the UK offers a safe, fast and efficient setting for clinical trials. Stakeholders should use the guidance to prepare for the changes and ensure their policies, procedures and systems are updated.

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 can be found here.

Further information about the clinical trials regulations reform, including a joint MHRA/HRA webinar about the implementation, can be found here.

 

Created with PollMaker

 

Topics